Literature DB >> 3753681

Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes.

D M Evans, R S Williams, C C Shone, P Hambleton, J Melling, J O Dolly.   

Abstract

Neurotoxin from Clostridium botulinum type B was purified to homogeneity by by affinity and ion-exchange chromatography; specific neurotoxicity of this protein (Mr of approximately equal to 155 000) following trypsinisation attained a level of 2 X 10(8) mouse LD50 units/mg protein. 125I-iodination of the toxin to high specific radioactivities (19-63 TBq/mmol) yielded typically greater than 65% of its original toxicity; dodecyl sulphate gel electrophoresis under reducing conditions, after trypsinisation, showed that the larger polypeptide (Mr of approximately equal to 101 000) was labelled preferentially. Saturable binding of the 125I-labelled neurotoxin to rat cerebrocortical synaptosomes was observed and Scatchard analysis showed a low content of acceptors with high affinity (Kd = 0.3-0.5 nM;Bmax approximately equal to 30-60 fmol/mg protein, together with a much larger population of weak-affinity sites. No significant differences in binding affinity were seen in competition experiments using native or fully activated (trypsinized) neurotoxin, indicating that chain cleavage is not essential for acceptor-toxin interaction. Type A botulinum neurotoxin showed a limited capacity to inhibit the synaptosomal binding of labelled type B toxin, even at high concentrations (1 muM), and other neurotoxins were without effect, emphasising the acceptor selectivity. Near-complete loss of specific toxin binding was produced by preincubation of synaptosomes with neuraminidase whereas inhibition of the low-affinity sites with wheat-germ agglutinin was less pronounced; such inactivation was prevented by inclusion of selective inhibitors (2,3-dehydro-2-deoxy-N-acetylneuraminic acid and N-acetylglucosamine, respectively). These observations implicate N-acetylneuraminic acid and, possibly, other sugar moieties as constituents of the toxin acceptors. Trypsinisation of synaptosomes gave incomplete inhibition of binding when assayed with 1 nM or 10 nM 125I-iodinated toxin. Detailed analysis of the actions of neuraminidase, trypsin and heat treatment on the concentration dependence of toxin binding suggest the existence of at least two distinguishable populations of sites that contain N-acetylneuraminic acid, with a protein component being associated with the acceptors of lower affinity. These findings are discussed in relation to those previously reported for type A neurotoxin and to the possible physiological significance of such membrane acceptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753681     DOI: 10.1111/j.1432-1033.1986.tb09413.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  21 in total

1.  Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes.

Authors:  S Kozaki; A Miki; Y Kamata; J Ogasawara; G Sakaguchi
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

Review 2.  Botulinum neurotoxin - from laboratory to bedside.

Authors:  K A Foster; H Bigalke; K R Aoki
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

3.  Clostridium botulinum types A, B, C1, and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes?

Authors:  E Somers; B R DasGupta
Journal:  J Protein Chem       Date:  1991-08

Review 4.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

5.  Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities.

Authors:  B Hallis; B A James; C C Shone
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

6.  Antigenic structure of Clostridium botulinum type B neurotoxin and its interaction with gangliosides, cerebroside, and free fatty acids.

Authors:  S Kozaki; J Ogasawara; Y Shimote; Y Kamata; G Sakaguchi
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

7.  Effect of pH on the interaction of botulinum neurotoxins A, B and E with liposomes.

Authors:  C Montecucco; G Schiavo; B R Dasgupta
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

8.  Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain.

Authors:  B Poulain; L Tauc; E A Maisey; J D Wadsworth; P M Mohan; J O Dolly
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  The Use of Botulinum Toxins for Chronic Pain and Headaches.

Authors:  Charles E. Argoff
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

10.  SV2 mediates entry of tetanus neurotoxin into central neurons.

Authors:  Felix L Yeh; Min Dong; Jun Yao; William H Tepp; Guangyun Lin; Eric A Johnson; Edwin R Chapman
Journal:  PLoS Pathog       Date:  2010-11-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.